Mechanisms of resistance to EGFR tyrosine kinase inhibitors

Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, e.g., gefitinib and elrotinib) have been effectively used for clinical treatment. However, patients eventually develop drug resistance. Resistance to EGFR-TKIs is inevitable due to various mechanisms, such as the secondary mutation (T790M), activation of alternative pathways (c-Met, HGF, AXL), aberrance of the downstream pathways (K-RAS mutations, loss of PTEN), impairment of the EGFR-TKIs-mediated apoptosis pathway (BCL2-like 11/BIM deletion polymorphism), histologic transformation, ATP binding cassette (ABC) transporter effusion, etc. Here we review and summarize the known resistant mechanisms to EGFR-TKIs and provide potential targets for development of new therapeutic strategies.

Abstract licence: CC BY-NC-ND

• Targeting cytokine and chemokine signaling pathways for cancer therapy · 2024

• Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance · 2022

• JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies · 2022

• Cancer Stem Cells—Key Players in Tumor Relapse · 2021

• A Marine Terpenoid, Heteronemin, Induces Both the Apoptosis and Ferroptosis of Hepatocellular Carcinoma Cells and Involves the ROS and MAPK Pathways · 2021

• A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials · 2021

• Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer · 2021

• Cell death-based treatment of lung adenocarcinoma · 2018

• Receptor Tyrosine Kinase-Targeted Cancer Therapy · 2018

• Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges · 2018

• Advances in studies of tyrosine kinase inhibitors and their acquired resistance · 2018

• On the Integration of In Silico Drug Design Methods for Drug Repurposing · 2017

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.